Dicerna Pharmaceuticals (NASDAQ:DRNA) had its price target boosted by SunTrust Banks to $20.00 in a report issued on Thursday, The Fly reports. They currently have a buy rating on the biopharmaceutical company’s stock.
A number of other equities research analysts also recently weighed in on DRNA. HC Wainwright reiterated a hold rating and issued a $14.00 price target on shares of Dicerna Pharmaceuticals in a research report on Tuesday, May 15th. BidaskClub downgraded shares of Dicerna Pharmaceuticals from a buy rating to a hold rating in a research report on Friday, June 8th. ValuEngine downgraded shares of Dicerna Pharmaceuticals from a strong-buy rating to a buy rating in a research report on Monday, July 2nd. Stifel Nicolaus lifted their price target on shares of Dicerna Pharmaceuticals from $18.00 to $20.00 and gave the company a buy rating in a research report on Thursday, August 9th. Finally, Chardan Capital reiterated a hold rating and issued a $14.50 price target on shares of Dicerna Pharmaceuticals in a research report on Monday, August 13th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the stock. Dicerna Pharmaceuticals has a consensus rating of Buy and a consensus target price of $15.54.
Shares of NASDAQ DRNA traded up $2.03 during midday trading on Thursday, reaching $15.05. The company’s stock had a trading volume of 133,763 shares, compared to its average volume of 432,725. The company has a current ratio of 5.40, a quick ratio of 5.40 and a debt-to-equity ratio of 0.14. Dicerna Pharmaceuticals has a fifty-two week low of $3.15 and a fifty-two week high of $17.50. The company has a market cap of $841.90 million, a price-to-earnings ratio of -3.99 and a beta of 2.43.
Dicerna Pharmaceuticals (NASDAQ:DRNA) last released its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.26). Dicerna Pharmaceuticals had a negative net margin of 1,642.81% and a negative return on equity of 97.39%. The business had revenue of $1.55 million during the quarter, compared to analyst estimates of $1.79 million. equities research analysts forecast that Dicerna Pharmaceuticals will post -1.14 earnings per share for the current year.
In other Dicerna Pharmaceuticals news, insider James B. Weissman sold 2,301 shares of the business’s stock in a transaction that occurred on Wednesday, September 5th. The shares were sold at an average price of $17.50, for a total transaction of $40,267.50. Following the completion of the transaction, the insider now directly owns 26,781 shares in the company, valued at $468,667.50. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Dennis Langer sold 14,531 shares of the business’s stock in a transaction that occurred on Wednesday, August 15th. The shares were sold at an average price of $16.00, for a total transaction of $232,496.00. Following the transaction, the director now owns 29,064 shares of the company’s stock, valued at $465,024. The disclosure for this sale can be found here. 19.85% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Cubist Systematic Strategies LLC acquired a new position in Dicerna Pharmaceuticals during the first quarter valued at approximately $102,000. Quantitative Systematic Strategies LLC bought a new stake in shares of Dicerna Pharmaceuticals during the first quarter worth $113,000. Caxton Corp bought a new stake in shares of Dicerna Pharmaceuticals during the first quarter worth $125,000. Jane Street Group LLC bought a new stake in shares of Dicerna Pharmaceuticals during the first quarter worth $136,000. Finally, State Board of Administration of Florida Retirement System bought a new stake in shares of Dicerna Pharmaceuticals during the second quarter worth $178,000. Institutional investors and hedge funds own 87.02% of the company’s stock.
Dicerna Pharmaceuticals Company Profile
Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia.
Featured Story: Risk Tolerance
Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.